DELCADE advises Mecadaq on the acquisition of Echeverria
On January 27, 2026 By Pierre-Antoine DUBECQ, Charlotte O'Leary, Fabrice DELOUIS, France Baumert and Mathilde Loulmet
DELCADE advised Mecadaq on the acquisition of Echeverria, further strengthening the group’s growth and consolidation strategy in the aerospace sector.
An acquisition aligned with Mecadaq’s external growth strategy
This acquisition forms part of Mecadaq’s external growth strategy and represents a first step in the implementation of a broader sector consolidation plan. Mecadaq has acquired 80% of the share capital of Echeverria, with the remaining 20% to be acquired at a later stage under a progressive acquisition structure.
Financed through senior bank debt arranged as part of the LBO, the transaction contributes to a wider development strategy aimed at expanding the group’s industrial capabilities and scope of expertise, while strengthening its strategic positioning in high value-added segments of the aerospace value chain.
The acquisition follows the entry of CAPZA into Mecadaq’s share capital alongside management in July 2025, through a significant reinvestment designed to support a new phase of development in France and internationally.
Mecadaq, a leading player in precision engineering for aerospace
Mecadaq is a leading precision engineering group serving the civil and defense aerospace sectors, with industrial operations in France and the United States. The group works with major industry players and relies on recognized expertise in the machining of complex mechanical parts for critical applications. In this context, Mecadaq is pursuing a growth trajectory combining external growth and organic development, in order to support its expansion in a transforming industry.
DELCADE’s role
DELCADE advised Mecadaq on all legal, tax and employment law aspects of the acquisition of Echeverria, having previously assisted the group’s shareholders in connection with CAPZA’s entry into its share capital. This involvement confirms DELCADE’s positioning alongside management teams and investors in complex external growth and high-end capital transactions.
DELCADE team
- Pierre-Antoine Dubecq, Partner – Corporate / M&A
- Fabrice Delouis, Partner and Co-founder of DELCADE, France Baumert, Partner, and Mathilde Loulmet, Associate – Tax
- Charlotte O’Leary, Partner – Employment law
Other advisors involved in the transaction
Buyer’s advisors:
Financial advisor: Etxe Finance (Romain Petit, Henri Hitier)
Financial due diligence: Forvis Mazars (Nicolas Guillo)
Seller’s advisors:
Financial advisor: Translead (Xavier Narbonne)
Legal advisor: Junqua-Lamarque & Associés
Lenders’ legal counsel:
Herbert Smith Freehills Kramer (Laure Bonin, Augustin Brulon)
A structuring transaction
This transaction illustrates DELCADE’s ability to support, over the long term, structuring projects serving the transformation and development of businesses.
Our latest news
Coordination of pension schemes: what legal framework applies to international careers?
International workforce mobility involves a complex interplay between several national social security systems. In terms of retirement, this raises major legal questions: which legislation applies to a posted or expatriate employee? How are their acquired rights preserved from one country to another? Under what terms will their pension ultimately be settled? These are questions our […]
Read
Shadow Payroll and International Assignments in France: a compliance guide for foreign employers
Foreign companies deploying employees or executives to France face a layered set of obligations that span employment law, payroll reporting, taxation, social security coordination, and immigration procedures. Managing these requirements in isolation — through separate providers across different jurisdictions — often leads to gaps, duplications, or costly errors. DELCADE’s International Assignment Services practice offers a […]
Read
DELCADE advises Geistlich Pharma AG on taking control of OST Développement
The European regenerative medicine market continues to consolidate. On 24 April 2026, the Swiss group Geistlich Pharma AG completed the acquisition of a majority stake in OST Développement, a French specialist in bone regeneration. DELCADE acted as legal counsel to the acquirer, extending a collaboration that began back in 2024. A two-stage M&A move The […]
Read